Table 2

Correlation analyses of PRO endpoints at month 3

HAQ-DISF-36v2† PFSF-36v2† BPPain-VASEQ-5D-3L P/D
Tofacitinib 5 mg twice daily (N=124)
 SF-36v2† PF10.70−0.59−0.51
 SF-36v2† BP1−0.78−0.62
 EQ-5D-3L P/D1
Tofacitinib 10 mg twice daily (N=119)
 SF-36v2† PF10.79−0.70−0.52
 SF-36v2† BP1−0.74−0.64
 EQ-5D-3L P/D1
Placebo (N=117)
 SF-36v2† PF10.72−0.63−0.48
 SF-36v2† BP1−0.78−0.63
 EQ-5D-3L P/D1
  • All correlations were ***p<0.001, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; the analysis included patients with observations at a visit of interest in Full Analysis Set.

  • †SF‑36v2 scores are norm-based.

  • BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions-3-level; HAQ‑DI, Health Assessment Questionnaire Disability Index; N, the number of patients included in calculating the sample correlation; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale.